Abstract:8546 Background: Mefatinib is an irreversible and highly effective EGFR and HER2 dual inhibitor. Although EGFR tyrosine kinase inhibitors are standard 1st line therapy for EGFR mutated non-small cell lung cancer (NSCLC), co-mutations, such as TP53 are associated with shorter PFS of EGFR TKI. Methods: Patients newly diagnosed with EGFR exon 19 deletion (19 del) or exon 21 L858R mutant (L858R), stage IIIB/IV NSCLC were enrolled and randomized at 2:1 ratio to receive mefatinib 60 mg PO QD or gefitinib 250 mg PO QD; The primary endpoint of the study was progression-free survival (PFS) per independent review committee (IRC). Archival tumor samples were analyzed using a 150 genes next-generation sequencing panel for biomarker analysis. Results: 336 eligible patients were assigned to receive mefatinib (n = 223) or gefitinib (n = 113). The median PFS of mefatinib was longer than gefitinib (13.73 vs. 9.66 months, hazard ratio [HR] = 0.68, P= 0.0024) and even longer in L858R subgroup (13.73 vs. 8.28 months, HR = 0.55). The data on overall survival (OS) were immature at the cut-off date ( < 40% events). 288 patients (189 in mefatinib and 99 in gefitinib) had available tumor samples for exploratory biomarker analysis. TP53 mutations were the most common disruptive concurrent alterations (45%). In patients with co-occurring disruptive mutations, mefatinib showed significant improvement in PFS compared to gefininib (12.55 vs 9.56 months, HR = 0.56, P= 0.0005; 12.55 vs 12.39 months, HR = 0.65, P= 0.0753 in 19del; and 13.70 vs 8.28 months, HR = 0.44, P= 0.0004 in L858R); Similarly, OS benefit of mefatinib was observed compared to gefitinib (not reached vs 26.68 months, HR = 0.54, P= 0.0045; not reached vs not reached, HR = 0.75, P= 0.4121 in 19del; and not reached vs 20.01 months, HR = 0.40, P= 0.0006 in L858R). Mefatinib had a favorable safety profile, with only 5.8% of patients experiencing dose reduction and less than 5% discontinuing treatment. Conclusions: Mefatinib is a new frontline option for EGFRmutant NSCLC. Co-occurring disruptive mutations caused decreased therapeutic efficacy of gefitinib, but had minimal impact on the PFS and OS of mefatinib. Comparing to gefitinib, PFS and OS improvements of mefatinib were most pronounced in patients with EGFR L858R mutation, especially those with disruptive co-occurring mutations. EGFR 19del or L858R mutation alone may not be sufficient to inform optimized front line therapies. Further studies are warranted to verify functional concurrent mutations for a better individualized precision medicine. Clinical trial information: CTR20192297.

Combined Targeting Of The Estrogen Receptor And The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects

Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib

Combined Tamoxifen and Gefitinib in Non-Small Cell Lung Cancer Shows Antiproliferative Effects.

The Synergistic Effect of EGFR Tyrosine Kinase Inhibitor Gefitinib in Combination with Aromatase Inhibitor Anastrozole in Non-Small Cell Lung Cancer Cell Lines

Antiproliferative Effects on Non-Small Cell Lung Cancer Cells by Combining Tamoxifen and Gefitinib

Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small-cell Lung Cancer on Progression-free and Overall Survival

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

EP1.03-11 Mechanisms of Gefitinib Plus Pemetrexed on Human Non-Small Cell Lung Cancer

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC

Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation

Combined Inhibition of Insulin-Like Growth Factor-1 Receptor Enhances the Effects of Gefitinib in a Human Non-Small Cell Lung Cancer Resistant Cell Line

Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells

Fulvestrant-Mediated Inhibition of Estrogen Receptor Signaling Slows Lung Cancer Progression

FGFR Inhibitors Combined with Nab-Paclitaxel - A Promising Strategy to Treat Non-Small Cell Lung Cancer and Overcome Resistance

Efficacy of Epidermal Growth Factor Receptor Inhibitors in Combination with Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment

Combined Inhibition Of The Egfr And Mtor Pathways In Egfr Wild-Type Non-Small Cell Lung Cancer Cell Lines With Different Genetic Backgrounds

Combined Egfr And Vegfr Versus Single Egfr Signaling Pathways Inhibition Therapy For Nsclc: A Systematic Review And Meta-Analysis